AstraZeneca (AZN) Price & Analysis

Compare

755 Followers

AZN Stock Chart & Stats

Day’s Range― - ―

52-Week Range9,573.51p - 13,388.00p

Previous CloseN/A

Volume91.53K

Average Volume (3M)2.82M

Market Cap

£182.65B

Enterprise Value176.61B

Total Cash (Recent Filing)£7.11B

Total Debt (Recent Filing)£32.84B

Price to Earnings (P/E)28.4

Beta0.99

Next Earnings

Nov 06, 2025

EPS Estimate

1.7

Last Dividend Ex-Date

Aug 07, 2025

Dividend Yield1.75%

Share Statistics

EPS (TTM)1.62

Shares Outstanding1,550,682,600

10 Day Avg. Volume3,093,686

30 Day Avg. Volume2,820,371

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

£13,409.09

Price Target Upside11.30% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering11

Bulls Say, Bears Say

Bulls Say

Earnings ProjectionsThe price target for AstraZeneca has increased by 9% due to upgrades, reflecting optimism about the company's long-term prospects.

Product DevelopmentFive unappreciated phase 3 catalysts in the non-oncology segment are expected to unlock significant upside for AstraZeneca's sales.

Bears Say

Market ChallengesAssuming low penetration due to difficulty in predicting market adoption in a heavily genericised market.

Potential DownsidesMain downsides to the 2031 group EBITA include potential growth issues with the Enhertu drug and the removal of Datroway from the model.

AstraZeneca News

FibroGen announces approval for FibroGen China sale to AstraZeneca

FibroGen (FGEN) announced that the China State Administration for Market Regulation approved the sale of FibroGen International to...

5d ago

AZN

FGEN

Trump Weekly: Trump weighs stake in Intel, candidates for Fed Chair

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by...

8d ago

AMD

AZN

AstraZeneca announces Flumist availability for home delivery

AstraZeneca (AZN) launched FluMist Home, the at-home delivery service for Flumist. Flumist is the first and only seasonal...

8d ago

AZN

Soros boosts exits stake in AstraZeneca, cuts position in Alphabet

George Soros’ Soros Fund Management disclosed in an SEC filing its holdings as of June 30, 2025. Soros’...

9d ago

Trump Trade: Pharma tariff announcement likely ‘weeks away’

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by...

9d ago

AZN

BMY

Pharma tariff announcement likely ‘weeks away,’ Reuters reports

The announcement by President Donald Trump’s administration of the results of a probe into pharmaceutical imports and new...

10d ago

AZN

BMY

Sector Spotlight: Trump administration seeks hometown discount from Big Pharma

Welcome to the latest “Sector Spotlight,” where The Fly looks at a new industry every week and highlights...

15d ago

AZN

BMY

Trump, pharma industry discuss increasing medicine spending abroad, Reuters says

The Trump administration has been talking to drugmakers about ways to raise prices of medicines in Europe and...

15d ago

AZN

BMY

Compugen price target raised to $13 from $10 at Leerink

Leerink raised the firm’s price target on Compugen (CGEN) to $13 from $10 and keeps an Outperform rating...

16d ago

AZN

CGEN

Trump Trade: U.S. proposes easing some restrictions on drones

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by...

17d ago

AZN

JKS

AstraZeneca’s New Asthma Study: Potential Market Impact

AstraZeneca (($AZN)), AstraZeneca plc (($GB:AZN)), AstraZeneca (($DE:ZEGA)), AstraZeneca plc US (($AZNCF)) announced an update on their ongoing clinical...

18h ago

AZN

AstraZeneca’s DESTINY-Endometrial01 Study: A New Horizon in Endometrial Cancer Treatment

AstraZeneca (($AZN)), AstraZeneca plc (($GB:AZN)), AstraZeneca (($DE:ZEGA)), AstraZeneca plc US (($AZNCF)) announced an update on their ongoing clinical...

18h ago

AZN

AstraZeneca’s ARISE Study: Real-World Insights on Acalabrutinib for CLL

AstraZeneca (($AZN)), AstraZeneca plc (($GB:AZN)), AstraZeneca (($DE:ZEGA)), AstraZeneca plc US (($AZNCF)) announced an update on their ongoing clinical...

18h ago

AZN

AstraZeneca’s Innovative Lung Cancer Screening Study: A Game Changer for Early Detection

AstraZeneca (($AZN)), AstraZeneca plc (($GB:AZN)), AstraZeneca (($DE:ZEGA)), AstraZeneca plc US (($AZNCF)) announced an update on their ongoing clinical...

18h ago

AZN

AZN FAQ

What was AstraZeneca PLC’s price range in the past 12 months?

AstraZeneca PLC lowest share price was 9573.50p and its highest was 13388.00p in the past 12 months.

What is AstraZeneca PLC’s market cap?

AstraZeneca PLC’s market cap is £182.65B.

When is AstraZeneca PLC’s upcoming earnings report date?

AstraZeneca PLC’s upcoming earnings report date is Nov 06, 2025 which is in 75 days.

How were AstraZeneca PLC’s earnings last quarter?

AstraZeneca PLC released its earnings results on Jul 29, 2025. The company reported 1.618p earnings per share for the quarter, beating the consensus estimate of 1.602p by 0.016p.

Is AstraZeneca PLC overvalued?

According to Wall Street analysts AstraZeneca PLC’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does AstraZeneca PLC pay dividends?

AstraZeneca PLC pays a Semiannually dividend of 76.7p which represents an annual dividend yield of 1.75%. See more information on AstraZeneca PLC dividends here

What is AstraZeneca PLC’s EPS estimate?

AstraZeneca PLC’s EPS estimate is 1.7.

How many shares outstanding does AstraZeneca PLC have?

AstraZeneca PLC has 1,550,682,600 shares outstanding.

What happened to AstraZeneca PLC’s price movement after its last earnings report?

AstraZeneca PLC reported an EPS of 1.618p in its last earnings report, beating expectations of 1.602p. Following the earnings report the stock price went up 3.411%.

Which hedge fund is a major shareholder of AstraZeneca PLC?

Currently, no hedge funds are holding shares in GB:AZN

AstraZeneca Stock Smart Score

Outperform

Fundamentals

Return on Equity

20.09%

Trailing 12-Months

Asset Growth

-0.61%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

AstraZeneca PLC

AstraZeneca (AZN) is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. Headquartered in Cambridge, UK, the company operates in various therapeutic areas including oncology, cardiovascular, renal, metabolism, respiratory, and immunology. AstraZeneca is known for its innovative drug pipeline and significant contributions to the treatment of diseases such as cancer, diabetes, and respiratory conditions. Its portfolio includes well-established products as well as new therapies that leverage cutting-edge research and development.

AstraZeneca (AZN) Earnings & Revenues

Historic Earnings Reports

AZN Stock 12 Month Forecast

Average Price Target

13,409.09p

▲(11.30% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10245":"10,245p","12184":"12,184p","14123":"14,123p","16062":"16,062p","18001":"18,001p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18000,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">18K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13409.09,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">13K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10900,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">11K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10245,12184,14123,16062,18001],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11026.95,11563.338461538462,12099.726923076923,12636.115384615385,13172.503846153846,13708.892307692307,14245.280769230769,14781.669230769232,15318.057692307691,15854.446153846155,16390.834615384614,16927.223076923077,17463.61153846154,{"y":18000,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11026.95,11210.191538461539,11393.433076923078,11576.674615384616,11759.916153846154,11943.157692307694,12126.399230769232,12309.64076923077,12492.882307692307,12676.123846153847,12859.365384615385,13042.606923076924,13225.848461538462,{"y":13409.09,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11026.95,11017.184615384616,11007.419230769232,10997.653846153848,10987.888461538461,10978.123076923077,10968.357692307693,10958.592307692308,10948.826923076924,10939.06153846154,10929.296153846153,10919.530769230769,10909.765384615384,{"y":10900,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12171.94,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12994.64,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11549.92,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10788.41,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10330.33,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10246.15,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11103.59,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11884.96,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11287.14,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 68,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10534.4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10500.63,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10329.82,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11026.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >